161 related articles for article (PubMed ID: 37914247)
21. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
Feng Y; Zhang Y; Shi J
Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
[TBL] [Abstract][Full Text] [Related]
22. Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.
Barbui T; De Stefano V; Falanga A; Finazzi G; Martinelli I; Rodeghiero F; Vannucchi AM; Barosi G
Blood Cancer J; 2019 Aug; 9(8):61. PubMed ID: 31395856
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
McMahon B; Stein BL
Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Dec; 149(12):1687-1693. PubMed ID: 35735335
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
Valladares X; Benavente R; Rojas C; Peña C; Valenzuela R; Monardes V; López H; Abarca M; León P; Osorio R; Pérez E; Soto P; Rocca G; Cardemil D; Torres V; Intriago M; Cabrera ME; Undurraga MS
Rev Med Chil; 2021 Nov; 149(11):1532-1538. PubMed ID: 35735314
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.
Martin K
Curr Hematol Malig Rep; 2017 Oct; 12(5):389-396. PubMed ID: 28948496
[TBL] [Abstract][Full Text] [Related]
27. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
28. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
[TBL] [Abstract][Full Text] [Related]
29. Does Race Play a Role in Complications and Outcomes of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?
Peseski AM; Saliba AN; Althouse SK; Sayar H
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):30-38. PubMed ID: 33607101
[TBL] [Abstract][Full Text] [Related]
30. Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms.
Zhang X; Cai X; Pan J
Clin Appl Thromb Hemost; 2020; 26():1076029620935207. PubMed ID: 32683889
[TBL] [Abstract][Full Text] [Related]
31. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms.
Hasselbalch HC; Elvers M; Schafer AI
Blood; 2021 Apr; 137(16):2152-2160. PubMed ID: 33649757
[TBL] [Abstract][Full Text] [Related]
32. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing.
Maddali M; Venkatraman A; Kulkarni UP; Mani S; Raj S; Sigamani E; Korula A; A FN; Lionel SA; Selvarajan S; Manipadam MT; Abraham A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2022 Sep; 101(9):1987-2000. PubMed ID: 35840818
[TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative Neoplasms in Children and Adolescents and Thrombosis at Unusual Sites: The Role of Driver Mutations.
Tafesh L; Musgrave K; Roberts W; Plews D; Carey P; Biss T
J Pediatr Hematol Oncol; 2019 Aug; 41(6):490-493. PubMed ID: 29668539
[TBL] [Abstract][Full Text] [Related]
35. [JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].
Wang JY; Ai XF; Xu JQ; Li QH; Xu ZF; Qin TJ; Zang Y; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):705-9. PubMed ID: 23336221
[TBL] [Abstract][Full Text] [Related]
36. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.
Gutwein O; Lavi N; Barzilai M; Shacham-Abulafia A; Leader A; Chubar E; Dally N; Shapira S; Mishchenko E; Ellis M; Koren-Michowitz M
Acta Haematol; 2021; 144(4):438-445. PubMed ID: 33316809
[TBL] [Abstract][Full Text] [Related]
37. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
Odenike O
Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
39. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Gugliotta L; Iurlo A; Gugliotta G; Tieghi A; Specchia G; Gaidano G; Scalzulli PR; Rumi E; Dragani A; Martinelli V; Santoro C; Randi ML; Tagariello G; Candoni A; Cattaneo D; Ricco A; Palmieri R; Liberati MA; Langella M; Rago A; Bergamaschi M; Monari P; Miglio R; Santoro U; Cacciola R; Rupoli S; Mastrullo L; Musto P; Mazzucconi MG; Vignetti M; Cortelezzi A; Vianelli N; Martino B; De Stefano V; Passamonti F; Vannucchi AM;
Leuk Res; 2016 Jul; 46():18-25. PubMed ID: 27107744
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
